Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Open accessThe DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index; 15 of the 101 sources its claims cite were checked for support.
Abstract
Colorectal cancer (CRC) is the second-leading cause of cancer-related mortality worldwide. CRC mortality results almost exclusively from metastatic disease (mCRC) for which systemic chemotherapy is often a preferred therapeutic option. Biomarker-based stratification of mCRC enables the use of precision therapy based on individual tumor mutational profiles. Activating mutations in the RAS/RAF/MAPK pathway downstream of EGFR signaling have, until recently, limited the use of EGFR-targeted therapies for mCRC; however, the development of anti-RAS and anti-RAF therapies together with improved strategies to limit compensatory signaling pathways is resulting in improved survival rates in several highly lethal mCRC sub-types (e.g., BRAF-mutant). The use of fluoropyrimidine (FP)-based chemotherapy regimens to treat mCRC continues to evolve contributing to improved long-term survival. Future advances in chemotherapy for mCRC will need to position development relative to the advances made in precision oncology.
Overview
CoChat Summary
TL;DR
This review summarizes recent advances in treating colorectal cancer (CRC), emphasizing biomarker-based stratification and targeted therapies for metastatic CRC (mCRC). It highlights progress in anti-EGFR, anti-RAS, anti-BRAF, anti-VEGF, fluoropyrimidine chemotherapy, and immunotherapy, while noting that mCRC survival remains poor.
Key findings
- CRC causes >930,000 deaths/year worldwide, with >1.9 million new diagnoses annually; by 2040, projections are >3.2 million new cases and >1.6 million deaths. mCRC 5-year survival remains <11%, though median overall survival now exceeds 32 months, improved from 22.6 months in 2012.
- RAS/RAF/MAPK mutations limit EGFR-targeted therapy: KRAS mutations occur in ~40% of mCRC, NRAS in 3–5%, and BRAF in ~8.5%, with BRAFV600E comprising two-thirds of BRAF mutations. BRAFV600E mCRC has median survival of 13.5 months vs. 30.6 months for BRAF wild-type tumors.
- KRASG12C occurs in <4% of mCRC; sotorasib produced objective responses in approximately 10% of patients, and adagrasib showed similar results. In BRAFV600E mCRC, encorafenib plus cetuximab increased objective response rate to 19.5% vs. 1.8% for control, and adding binimetinib increased it to 26.8%.
- Fluoropyrimidine doublets remain central: adding oxaliplatin to 5-FU/LV increased response rate (50.7% vs. 22.3%) and progression-free survival (9.0 vs. 6.2 months), while adding irinotecan improved response rate (49% vs. 31%) and overall survival (17.4 vs. 14.1 months). Immunotherapy is approved for dMMR/MSI-high mCRC, which is <5% of mCRC cases, with some estimates that only 2% of mCRC patients are candidates for successful immune checkpoint blockade.
Methods
- Design: narrative review of therapeutic strategies for CRC, with emphasis on mCRC.
- Data/sample: published literature and clinical trial results; no primary patient cohort or new experimental data are reported.
- Main analysis: narrative synthesis of biomarker-based stratification, targeted therapy development, chemotherapy regimens, and immunotherapy approaches.
Limitations
- Stated: reported survival improvements are often based on clinical trials involving a small percentage of patients, often with favorable performance characteristics; 5-year mCRC survival remains dismal.
- Evident from text: as a narrative review, it does not describe a systematic search strategy, formal quality assessment, or meta-analysis, and it presents no primary data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
13 Valid · 4 Not valid · 69 Not checked · 19 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Studies combining cetuximab with anti-IGF-1R therapies [54,55] have not yet yielded favorable clinical outcomes that would be consistent with this approach overcoming acquired resistance to anti-EGFR therapy.”
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 3. Targeting EGFR in mCRC > 3.3. Alternative Targets in EGFR-Resistant mCRC
What the sources say
- Supportedcites [54] Reidy, 2010, Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer, J. Clin. Oncol. source
In “IMC-A12 in Refractory Anti-EGFR mAb Colorectal Cancer” (page not provided), the authors conclude that IMC-A12 with or without cetuximab was inactive in all but one of 64 patients previously treated with anti-EGFR therapy. The selected group with a prior prolonged anti-EGFR response showed no additional clinical activity, supporting the claim that this combination had not yielded favorable outcomes for overcoming resistance. (LLM, conf=0.92)
- Not checked yetcites [55] Sclafani, 2015, A Randomized Phase II/III Study of Dalotuzumab in Combination with Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer, J. Natl. Cancer Inst. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“precision targeting based on the specific mutational profiles of individual CRC tumors is playing an important role [12].”
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 1. Introduction
What the sources say
- Supportedcites [12] Koroukian, 2023, Receipt of Targeted Therapy and Survival Outcomes in Patients with Metastatic Colorectal Cancer, JAMA Netw. Open source
The Introduction (page unavailable) says that molecular profiling informs the choice of targeted therapy for mCRC. The Results (page unavailable) report a clear survival advantage with EGFR inhibitors in patients with RAS-wild-type tumors, supporting the claim's broad point about mutation-guided targeting. The paper notes that survival findings for other targeted therapies were mixed. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recent studies with the KRASG12D specific inhibitor MRTX1133 [85] have, however, showed promise that this mutant form of KRAS is also druggable.”
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 4. Targeting Mutant KRAS
What the sources say
- Supportedcites [85] Hallin, 2022, Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor, Nat. Med. source
The Significance section identifies MRTX1133 as a KRAS G12D-selective inhibitor active in vitro and in vivo, with tumor regression in multiple xenograft models. The Discussion states that these preclinical findings demonstrate the feasibility of developing mutation-selective KRAS G12D inhibitors. This supports the claim that the studies show promise for drugging KRAS G12D; it does not imply clinical efficacy. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Multiple agents targeting both canonical and the β-catenin-independent non-canonical Wnt signaling including v-ATPase inhibitors and anti-RSPO antibody are undergoing clinical trials in CRC and other malignancies [119,120].”
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 7. Wnt-Pathway Targeting
What the sources say
- Partly supportedcites [119] Park, W.J., and Kim, M.J. (2023). A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities. Cells, 12. sourceExperimental — accuracy not yet measured
Section 3.3 says v-ATPase inhibitors are undergoing phase 2 trials, and section 3.1 describes trials of a DKK1 antibody while noting DKK1’s reported connection to non-canonical Wnt signaling. But section 3.2 says the anti-RSPO3 antibody completed its phase 1 trial, not that it is undergoing one. The paper also describes v-ATPase inhibitors as suppressing Wnt/β-catenin signaling, rather than the β-catenin-independent pathway. (LLM, conf=0.85)
- Partly supportedcites [120] Zhao, 2022, Wnt signaling in colorectal cancer: Pathogenic role and therapeutic target, Mol. Cancer sourceExperimental — accuracy not yet measured
The Drugs and inhibitors section (Tables 2–3; page not provided) describes agents affecting canonical Wnt/β-catenin signaling and lists Box 5 as an inhibitor of Wnt5a-induced signaling. It also describes SM08502 as clinically used for solid tumors. However, the cited passages do not identify v-ATPase inhibitors or anti-RSPO antibodies as agents undergoing clinical trials in CRC or other malignancies. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“while regorafenib whose targets include VEGF-R1, VEGF-R2, and VEGF-R3 or Fruquintinib is used in combination with TAS-102 (combination of trifluridine and Tiperacil) for third-line treatment [128].”
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 8. Targeting VEGFR
What the sources say
- Partly supportedcites [128] Li, 2021, Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review, Front. Oncol. sourceExperimental — accuracy not yet measured
The Introduction and ‘Current Status of the Third-Line Regimen’ (page not supplied) identify regorafenib, fruquintinib, and TAS-102 as third-line treatments for mCRC. They do not say that regorafenib or fruquintinib is used in combination with TAS-102; the paper discusses them as separate options. The Current Status section does support the cited sentence’s VEGFR1/2/3 targets for regorafenib. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
43 more claims · 2 with their cited sources checked
Create a free account to see all 105 claims and to verify the 86 references still open.
- It may state two separate claims as one. 52
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This type of targeted therapy is only effective in the absence of mutations in the RAS and BRAF genes.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors are widely used to treat melanoma with BRAF-V600 mutations, and encorafenib is also approved, in combination with cetuximab, for metastatic CRC with BRAF-V600E mutation, which is the predominant BRAF mutation in CRC [29].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, acquired resistance to BRAF-targeted therapies in BRAF-mutated CRC is a significant challenge, but it may potentially be overcome using combinations of anti-BRAF and anti-EGFR therapies with inhibitors of MEK, Wnt, or cyclin-dependent kinases CDK4/6 [29].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Activating mutations in the RAS/RAF/MEK/ERK signaling pathway downstream of EGFR generally confer resistance to anti-EGFR therapies; however, recent developments have led to new approaches for therapeutically targeting CRC with RAS or BRAF mutations [29].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“For instance, a combination of anti-EGFR therapy with a MEK inhibitor, such as selumetinib or pimasertib, could potentially limit acquired resistance to anti-EGFR antibody therapy from activating mutations in RAS or BRAF [29].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 3. Targeting EGFR in mCRC
“The formation of either homo- or heterodimers is possible resulting in 28 possible combinations”
§ Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment > 3. Targeting EGFR in mCRC
“The EGFR family includes HER2/Neu/ERBB2, HER3/ERBB3, and HER4/ERBB4 in addition to EGFR/ErbB1/HER1.”
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“Approaches for precision targeting of mCRC sub-types derive from an understanding of colorectal carcinogenesis initiated in the pioneering work of Fearon and Vogelstein [17].”
BackgroundBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“The anti-VEGF antibody bevacizumab (BEV) is used in combination with chemotherapy (FOLFOX or FOLFIRI) for the treatment of mCRC with activating mutations in the RAS/RAF/MAPK pathway [121].”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“A rationale for combining anti-VEGF therapy with chemotherapy is that anti-VEGF therapy caused tumor vasculature to normalize resulting in increased drug delivery to tumors [123].”
Background5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 1×
“5-Fluororuracil (5-FU) was introduced into the clinic >60 years ago, and its use in the adjuvant setting in combination with folinic acid (leucovorin (LV)) was shown to decrease the risk for disease recurrence for patients with primary colon cancer [8,9].”
Backgroundde Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 1×
“%) and longer time to progression (6.7 vs. 4.4 months), but, in this case, overall survival benefit was significantly increased (17.4 vs. 14.1 months) [140].”
BackgroundInfluentialTournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · cited 1×
“The alternative FP doublet therapy is often used for second-line treatment following disease progression (e.g., FOLFOX (1st) → FOLFIRI (2nd)), and there is no evidence for a preferred sequencing of these regimens [141].”
BackgroundGlobal burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN
Morgan, E., Arnold, M., Gini, A., Lorenzoni, V, Cabasag, C. J., Laversanne, M., Vignat, J., Ferlay, J., Murphy, N., & Bray, F. (2023) · Gut · doi:10.1136/gutjnl-2022-327736 · Cited by 2,429 · cited 1×
“CRC collectively is a leading cause of cancer-related mortality worldwide resulting in >930,000 deaths [1].”
BackgroundGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“Consistent with BRAF V600E mutation, signaling independent of upstream input, anti-EGFR therapy is not useful in patients with BRAF V600E tumors as single agents [93] or in combination with chemotherapy [94].”
Background
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Activating mutations in the RAS/RAF/MEK/ERK signaling pathway downstream of EGFR generally confer resistance to anti-EGFR therapies; however, recent developments have led to new approaches for therapeutically targeting CRC with RAS or BRAF mutations [29].”
InfluentialTardito, S., Matis, S., Zocchi, M. R., Benelli, R., & Poggi, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137131 · Cited by 34
Biohybrid Microrobot Enteric‐Coated Microcapsule for Oral Treatment of Colorectal Cancer
Kang, Y., She, Y., Zang, Y., Yuan, M., Niu, G., Tian, X., Zhang, L., Lin, J., Yang, M., Pei, Z., et al. (2025) · Advanced Materials · doi:10.1002/adma.202420586 · Cited by 29
Lopez, B. A. A., Pinto-Colmenarez, R., Caliwag, F. M. C., Ponce-Lujan, L., Madera, M. D. F., Cortés, A. V. G., Martínez, A. G. M., Martinez, I. G. Z., & León, F. G. (2024) · Cureus · doi:10.7759/cureus.70933 · Cited by 31
“Still, further research is needed to evaluate these treatments [75-77].”
BackgroundOkechukwu, C. C., Ma, X., Sah, N., Mani, C., Palle, K., & Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16071360 · Cited by 21
Self-citation
Metadata
- Authors
- Gmeiner, W. H.
- Affiliations
- Wake Forest University Health Sciences (US)
- Corresponding author
- Gmeiner, William H.
- ORCID
- Gmeiner, William H.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-03-02
- Volume
- 16
- Issue
- 5
- Pages
- 1029
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC10930828
- OpenAlex
- W4392375125
- Cited by
- 78
- References
- 150
- Citations by year
- 2026: 27 · 2025: 37 · 2024: 14
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- NIH-NCI (R42 CA254843-02A1, P30 CA 012197, CA200460)
- Department of Defense Peer Reviewed Cancer Research Program (R42 CA254843-02A1, P30 CA 012197, CA200460)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- colorectal cancer, metastatic colorectal cancer, anti-EGFR therapy, RAS/MAPK pathway, BRAF mutation, compensatory signaling, fluoropyrimidine chemotherapy, precision oncology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment. https://app.cochat.ai/papers/10.3390/cancers16051029
- The paper
- Gmeiner, W. H. (2024). Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment. Cancers. https://doi.org/10.3390/cancers16051029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.